Notice of Allowance received and, once granted, the new U.S. patent is expected to be valid until 2034 NDA submission is expected in H1/2019, with eligibility for 6-month priority review; Subject to FDA approval, U.S. commercial launch with RedHill’s existing sales force is planned for ...
TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the ...
TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the ...
TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. pylori eradication (84% vs. 58%) with high degree of statistical significance (p ...
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases and cancer, today ...
Key Highlights: Top-line results from the confirmatory Phase III study with TALICIA ® for H. pylori infection are on track to be announced by year-end 2018, with potential NDA filing in early 2019 Positive top-line results from the Phase III study with RHB-104 for Crohn’s disease - the study ...
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
Top-line results from the ERADICATE Hp2 confirmatory Phase III study expected before year-end 2018 H. pylori bacterial infection affects over 50% of the adult population worldwide and 30-40% of the U.S. population TEL-AVIV, Israel and RALEIGH, N.C. , Oct. ...
Menu